PDCD1 and classic Hodgkin lymphoma: Clinical trials have demonstrated high response rates of up to 87% by PD-1 blockade in relapsed and refractory CHL (17, , , , –22), indicating the importance of the PD-1/PD-L1 biology in the disease.